SYDNEY, May 8, 2025 /PRNewswire/ -- Great Place To Work® Australia proudly announces its 2025 Best Workplacesâ„¢ in Technology List, honouring 55 of the nation's most outstanding technology employers. Now in its third year, this prestigious list recognises organisations that lead with trust, purpose, and innovation, elevating employee experience and setting benchmarks for excellence in the tech industry.
Recognising Excellence in a Fast-Moving Sector
Technology is a thriving industry in Australia, with forecasts predicting it will contribute A$250 billion to the national economy by 2030. In 2023, the Minister for Skills and Training, the Hon Brendan O'Connor, noted that Australia's tech workforce had grown 8% year-on-year, placing the country on track to achieve the national goal of 1.2 million technology-related jobs by 2030.
As one of the fastest-growing sectors, technology is crucial in driving employment. The 2025 Best Workplaces in Technology List highlights the organisations that are helping this growth by building workplaces based on trust, inclusivity and purpose.
The 2025 list is based on confidential employee feedback from 28,102 voices across Australia's tech sector, rigorously evaluated through the Great Place To Work Trust Indexâ„¢ survey. While the methodology remains unchanged, the stories of progress, empowerment, and resilience continue to evolve.
"The 2025 Best Workplaces in Technology list celebrates 55 companies that are not only great employers but powerful industry leaders," said Rebecca Moulynox, General Manager, Great Place To Work Australia & New Zealand. "What sets these organisations apart is their ability to foster innovation through cultures of trust, purpose, and inclusion. In a highly competitive and fast-moving sector, these companies are proving that strong leadership and a great employee experience are key drivers of sustained performance and market advantage."
Top Performers: Where Innovation Meets Impact
This year, CrowdStrike, which has demonstrated impressive technological advancements through innovations such as Charlotte AI, takes the top spot in the medium and large category. CrowdStrike excels in inclusive leadership, mental health initiatives, and community engagement; they build a culture where well-being is a priority.
Smokeball ranks among the top for its exceptional employee-centred practices, including a $1,000 wellness allowance, dedicated 'reboot days' and robust hybrid work flexibility. Their holistic well-being programmes have led to lower employee turnover and demonstrated high morale across the organisation.
Centorrino Technologies (CT) makes a notable debut with a strong people-first approach, carbon neutrality since 2019, and a bold goal to offset all historical emissions by 2025. Their inclusive workplace is grounded in empathy, empowerment, and community partnerships, like supporting EatUp.
What Makes These Workplaces Stand Out?
All companies on this year's list share a foundation of high-trust workplace cultures. They invest in leadership, employee development, mental health, and purpose-driven strategies. From flexible work environments and structured recognition programs to community initiatives and sustainability goals, these companies exemplify what it means to lead through people.
Notable standouts include:
- Atlassian, returning for the third year with its flexible Team Anywhere model and AI-powered collaboration tools.
- Cisco, for cultivating a "Conscious Culture" that embraces inclusion, mental health, and environmental stewardship.
- REA Group, with a 99% retention rate among new leaders and a deep commitment to mental wellbeing and cultural empowerment.
- AirTrunk, which combines internal mobility and inclusive leadership with socially impactful initiatives funded by Sustainability Linked Loans.
- Mantel Group, disrupting traditional hierarchies to empower teams with trust and autonomy.
Raising the Bar for Australia's Tech Ecosystem
This year's list doesn't just recognise great companies but shows that in an era defined by rapid digital transformation and talent competition, workplace culture is not just a people priority but it's essential for business success.
Early trends reinforce that employee-centric practices drive business performance, from better retention to stronger employer branding and innovation outcomes. As such, the 2025 Best Workplaces in Technology List serves as both a recognition and a call to action for the industry.
Explore the Full List
To view the complete list of Australia's Best Workplaces in Technology 2025 and learn how your organisation can earn recognition next year, visit the Great Place To Work Australia website.
About Great Place To Work
Great Place To Work is the global authority on workplace culture. Our mission is to help every place become a great place to work for all. We give leaders and organisations the recognition and tools to create a consistently and overwhelmingly positive employee experience, fostering cultures that are proven to drive business, improve lives, and better society. Our recognition is the most coveted and respected in the world for elevating employer brands to attract the right people. Our proprietary methodology and platform enable organisations to truly capture, analyse, and understand the experience of all employees. Our groundbreaking research empowers organisations to build cultures that retain talent and unlock the potential of every employee. Our coaches, content, and community connect the boldest leaders, ideas, and innovations in employee experience. Since 1992, our Certificationâ„¢, Best Workplaces Lists, and global benchmarks have become the industry standard, built on data from more than 100 million employees in 150 countries around the world.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Great Place To Work® Announces Australia's Best Workplaces™ in Technology List 2025
NEWARK, Del., May 10, 2026 /PRNewswire/ -- ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-based authorization model. This policy shift addresses the industry-wide challenge of compliance delays by embedding intellectual property clearance directly into the procurement process, thereby empowering global biopharmaceutical innovation with a more efficient and barrier-free R&D experience.
The official statement reads as follows:
The innovative development of biopharmaceuticals relies on stable, legally compliant R&D tools. Functional cell lines serve as a versatile vital engine driving full-cycle breakthroughs in innovative drug R&D, and the ease of obtaining usage authorization for functional cell lines directly impacts projects timelines. To simplify compliance arrangements and reduce administrative burdens for global partners, ACROBiosystems has upgraded its global permitted use policy for HEK293 functional cell line products. The updated framework provides an expansive scope of usage rights to encompass not only internal research but also certain activities from early discovery well into clinical development. It provides clear and standardized legitimate usage scopes and removes redundant review steps, enabling researchers to conduct R&D activities in full compliance with IP and contractual requirements. Customers operating within the defined permitted use scope are now exempt from additional license processing and associated cost, allowing them to focus on core drug R&D and accelerate project progress, with greatly improved efficiency.
- Core Policy & Compliance Framework
The upgraded policy simplifies compliance processes while establishing clear legitimate usage boundaries. Customers operating within the defined permitted use scope below are entitled to utilize HEK293 functional cell line products for specified activities without additional application or approval.
1.Permitted Usage Scope
HEK293 functional cell line products are authorized for use in internal research, drug discovery, assay development, internal quality assurance (QA) testing and lot release analysis.
*Note: For all other commercial uses beyond the above scopes, customers shall contact ACROBiosystems to obtain a license through flexible options.
2.Regional & Usage Notes
This policy applies to all global markets except the Greater China region, delivering seamless, efficient access to the HEK293 functional cell line products for research and development activities. By eliminating unnecessary administrative hurdles, this streamlined compliance approach empowers global researchers to redirect their focus toward core R&D priorities—rather than navigating complex compliance procedures.
For users in the Greater China region, the HEK293 functional cell line products are permitted for research use only, with separate official authorization required for any extended usage needs.
With localized teams across the United States, Europe and the Asia-Pacific area, ACROBiosystems provides dedicated policy guidance and one-stop compliance consulting tailored to this HEK293 functional cell line global license upgrade. Our regional experts offer timely interpretation of updated usage rules, streamlined consultation for scope expansion requests, and professional technical backing, helping global customers quickly adapt to the new policy and carry out functional cell line-related R&D in a fully compliant, efficient manner.
This policy upgrade further clarifies global permitted-use terms for HEK293 functional cell line products, streamlines daily compliance management, and lowers overall operational and compliance costs for global drug developers. By establishing a clearer, more flexible global compliance framework, ACROBiosystems enables the standardized, orderly and scalable expansion of HEK293 functional cell line compliant applications across diverse R&D scenarios. Moving forward, we will continue to optimize global IP governance and licensing mechanisms, deliver regulated, transparent and user-friendly functional cell line solutions, and support customers in exploring broader preclinical and translational research possibilities with fully compliant functional cell line resources, jointly accelerating high-quality innovative drug development worldwide.
About ACROBiosystems Group
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
